SMMT icon

Summit Therapeutics

18.82 USD
+0.00
0.00%
At close Jan 8, 4:00 PM EST
After hours
19.04
+0.22
1.17%
1 day
0.00%
5 days
3.12%
1 month
0.86%
3 months
-0.42%
6 months
140.05%
Year to date
2.56%
1 year
515.03%
5 years
1,197.93%
10 years
84.69%
 

About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Employees: 105

0
Funds holding %
of 6,810 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

237% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 19

226% more capital invested

Capital invested by funds: $567M [Q2] → $1.85B (+$1.28B) [Q3]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

43% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 35

34% more funds holding

Funds holding: 122 [Q2] → 163 (+41) [Q3]

1.33% more ownership

Funds ownership: 10.35% [Q2] → 11.68% (+1.33%) [Q3]

26% less call options, than puts

Call options by funds: $55.9M | Put options by funds: $75.5M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
59%
upside
Avg. target
$34
83%
upside
High target
$44
134%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
Asthika Goonewardene
17% 1-year accuracy
4 / 24 met price target
86%upside
$35
Buy
Initiated
8 Jan 2025
Wells Fargo
Mohit Bansal
29% 1-year accuracy
7 / 24 met price target
59%upside
$30
Overweight
Initiated
11 Dec 2024
Jefferies
Brent Thill
69% 1-year accuracy
37 / 54 met price target
65%upside
$31
Buy
Initiated
6 Dec 2024
HC Wainwright & Co.
Mitchell Kapoor
27% 1-year accuracy
45 / 164 met price target
134%upside
$44
Buy
Reiterated
18 Nov 2024
JMP Securities
Reni Benjamin
8% 1-year accuracy
3 / 36 met price target
70%upside
$32
Market Outperform
Initiated
4 Nov 2024

Financial journalist opinion

Based on 10 articles about SMMT published over the past 30 days

Neutral
Business Wire
2 days ago
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will present a corporate overview and an update on the progress of our organization, including the d.
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
The Motley Fool
5 days ago
Prediction: These 3 Healthcare Stocks Will Soar in 2025
No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good.
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Positive
Seeking Alpha
6 days ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Best-Performing Stocks Of 2024
Positive
The Motley Fool
1 week ago
3 Stocks That Could Be Monster Winners in 2025
What do many kids like most about the coming of a new year? The fireworks.
3 Stocks That Could Be Monster Winners in 2025
Positive
The Motley Fool
2 weeks ago
Where Will Summit Therapeutics Be in 5 Years?
Summit Therapeutics (SMMT 8.36%) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340% since January 2023.
Where Will Summit Therapeutics Be in 5 Years?
Positive
The Motley Fool
2 weeks ago
3 Stocks That Could Turn $1,000 into $5,000 by 2030
A five-bagger in only five years? Any investor would love to buy such a stock.
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Neutral
The Motley Fool
3 weeks ago
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Positive
The Motley Fool
3 weeks ago
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (VKTX -1.75%) and Summit Therapeutics (SMMT -0.22%) more than doubled in 2024.
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Positive
The Motley Fool
3 weeks ago
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced life-changing returns in much shorter time frames.
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Neutral
Business Wire
3 weeks ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™